Quanterix gains access to ImmunArray brain injury biomarker portfolio and ImmunArray gains access to Quanterix state of the art digital biomarker technology

Richmond, Va. and Lexington, Mass., September 28, 2016 – Quanterix Corporation, a company digitizing biomarker analysis to accurately measure change for precision health, today announced it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy. As part of the deal, ImmunArray gains access to Quanterix Simoa technology. Both companies are pioneering new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.

According to the U.S. Department of Health and Human Services, nearly one-third of all injury-related deaths in the U.S. involve a traumatic brain injury (TBI). Further, about 75 percent of TBIs that occur each year are concussions or other forms of mild TBI, which are far more difficult to diagnose. With this agreement, Quanterix and ImmunArray will work together to continue advancing research and technology in order to provide an accurate method for detecting mild to moderate traumatic brain injury in the future. Also, Quanterix will add select ImmunArray markers to its multiplexing panel for the neurology research market. These additions provide researchers with the ability to measure multiple proteins simultaneously at the single molecule level using Quanterix’ Simoa technology.

“This investment and collaboration agreement enhance our two companies’ collective ability to provide the broadest portfolio of biomarker panels to the research market utilizing highly sensitive technology,” said Donna Edmonds, chairman and CEO of ImmunArray. “As we continue to advance the research and development of panels for the detection and diagnosis of traumatic brain injury and other neurodegenerative diseases in acute and chronic settings, we will now have added support from Quanterix to help accelerate the development of important diagnostic tools. We welcome this vote of confidence from our colleagues at Quanterix and look forward to working closely with them.”

“We are excited to expand our collaboration with ImmunArray,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “ImmunArray has built an attractive portfolio of brain health biomarkers that nicely complement our existing menu of assays. We are also delighted that they will utilize our Simoa technology to further develop their portfolio for clinical utility.”

ImmunArray and Quanterix are both privately held, funded largely through venture capital investments and have been grant recipients of the GE-NFL Head Health Challenge to continue their work in improving diagnosis and treatment for mild to moderate traumatic brain injury. To learn more about Quanterix, please visit: www.quanterix.com. To learn more about ImmunArray, please visit www.immunarray.com.

About ImmunArray
Co-located in Rehovot, Israel and Richmond, Va., ImmunArray is a privately funded molecular diagnostics company dedicated to the development of novel blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company, which has introduced its first commercial tests based on its iCHIP platform, is currently conducting research in collaboration with leading clinicians and medical centers in the U.S. and Israel. The company was a grant recipient of the GE-NFL Head Health Challenge as well as secured additional corporate research funding to conduct research into the use of biomarkers to identify traumatic brain injury.

About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to accurately measure change for precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.